ダウンロード数: 251

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
49_5.pdf335.09 kBAdobe PDF見る/開く
タイトル: The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer
その他のタイトル: 前立腺癌診断におけるPSA-ACTおよびPSA-ACT volume indexの有用性についての検討
著者: Yamanaka, Kazuki
Yamada, Yuji
Kobayashi, Yasuhiro
Ueno, Koichi
Takechi, Yoshizumi
Hasegawa, Emi
Chikahira, Yoshimi
著者名の別形: 山中, 和樹
山田, 裕二
小林, 康浩
上野, 康一
武市, 佳純
長谷川, 絵美
近平, 佳美
キーワード: Prostate cancer
Prostate specific antigen alpha-l-antichymotrypsin
Transtion zone
発行日: Jan-2003
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 49
号: 1
開始ページ: 5
終了ページ: 10
抄録: 対象は1999年7月から28ヵ月間に超音波ガイド下経直腸的前立腺生検を施行したPSA2.0~10.0ng/mlの151例で, PSA, PSA-ACT, PSAD, PSATZD, PSA-ACTD, PSA-ACTTZDを測定し, ROC解析を用いてこれらのパラメーターを検討した.系統的6ヶ所生検にて151例中36例から前立腺癌が検出された.ROC解析ではPSA-ACTTZDのAUCが最大となり, PSA-ACTTZDは有意差をもってPSA単独より有用な指標と考えられた.PSA-ACTTZDのカットオフ値を0.20ng/ml2を設定することにより, 感度90%, 特異度55%で不必要な生検を回避できる可能性が示唆された
We examined the usefulness of prostate specific antigen alph-1-antichymotrypsin complex (PSA-ACT) and its indices for the detection of prostate cancer in patients with a prostate specific antigen (PSA) level between 2.1 and 10.0 ng/ml. Between July 1999 and October 2001, 151 patients with a PSA level between 2.1 and 10.0 ng/ml underwent a systematic biopsy under transrectal ultrasound (TRUS) guidance. The clinical values of total PSA, PSA-ACT, PSA density (PSAD), PSA-ACT density (PSA-ACTD), PSA transition zone density (PSATZD) and PSA-ACT transition zone density (PSA-ACTTZD) for the detection of prostate cancer were compared by using receiver operating characteristic (ROC) curve analysis. Of the 151 patients, 36 (23.8%) were histologically confirmed as having prostate cancer. The differences between patients with prostate cancer and benign prostatic disease were significant with respect to the PSA and PSA-ACT related parameters examined in this study. According to ROC curve analysis, the area under the curve (AUC) of PSA-ACTTZD was the greatest of all the parameters. The differences was significant between the AUC of PSA-ACTTZD and total PSA (p < 0.05). The cutoff value of PSA-ACTTZD with 0.20 ng/ml2 showed the highest sum of sensivitity (90%) and specificity (55%). Also, in 86 patients with a PSA level between 2.1 and 6.0 ng/ml, the AUC of PSA-ACTTZD was the greatest of all the parameters. Measuring the level of PSA-ACT and its indices may provide a better differentiation of prostate cancer and benign prostatic disease than total PSA alone in patients with intermediate PSA levels. PSA-ACTTZD is the most useful indicator among PSA-ACT and its volume indices.
URI: http://hdl.handle.net/2433/114903
PubMed ID: 12629773
出現コレクション:Vol.49 No.1

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。